睿昂基因(688217) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥56,884,419.55, representing a year-on-year increase of 17.84%[5] - Total revenue for Q1 2023 was ¥56,884,419.55, an increase of 18% compared to ¥48,273,660.16 in Q1 2022[17] - The net profit attributable to shareholders was ¥1,290,913.02, with a significant increase in sales volume compared to the same period last year[9] - Net profit for Q1 2023 was a loss of ¥5,300,038.19, slightly improved from a loss of ¥5,603,144.65 in Q1 2022[19] - Operating profit for Q1 2023 was a loss of ¥2,681,130.86, compared to a loss of ¥6,386,287.06 in Q1 2022, indicating a reduction in losses[18] - The company reported a total comprehensive loss of ¥5,300,038.19 for Q1 2023, compared to a loss of ¥5,603,144.65 in Q1 2022[19] Cash Flow - The net cash flow from operating activities reached ¥36,611,099.54, an increase of 1,153.46% year-on-year due to higher cash receipts from sales[6] - Cash inflow from operating activities in Q1 2023 was ¥119,526,990.15, significantly higher than ¥56,692,989.99 in Q1 2022, marking a 111% increase[19] - The net cash flow from operating activities for Q1 2023 was $36,611,099.54, a significant increase from $2,920,801.28 in Q1 2022, representing a growth of approximately 1,150%[20] - The total cash flow for the quarter resulted in a net decrease of $33,759,015.64, contrasting with an increase of $8,826,862.90 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,063,819,121.00, a decrease of 1.76% from the end of the previous year[6] - The company's current assets totaled ¥580,238,253.67, down from ¥624,479,327.42, indicating a decrease of about 7.1%[14] - Total liabilities decreased to ¥97,697,195.22 in Q1 2023 from ¥111,500,983.32 in Q1 2022, a reduction of approximately 12.4%[17] - The company reported a total of ¥42,839,952.35 in accounts payable, down from ¥51,180,535.03, indicating a decrease of approximately 16.5%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,363[11] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, accounting for 18.31% of the total shares[11] - Shareholders' equity attributable to the parent company increased to ¥938,186,855.60 in Q1 2023 from ¥936,895,942.58 in Q1 2022[17] Research and Development - Research and development expenses totaled ¥14,436,134.44, which is a decrease of 27.65% compared to the previous year, accounting for 25.38% of operating revenue, down by 15.95 percentage points[6] - Research and development expenses for Q1 2023 were ¥14,436,134.44, down from ¥19,953,750.23 in Q1 2022, a decrease of 27.5%[17] - The company has not provided any new product or technology development updates in the current report[13] Government Subsidies - The company received government subsidies amounting to ¥312,735.06, which are closely related to its normal business operations[7] Market and Future Outlook - There are no significant market expansion or acquisition strategies mentioned in the report[13] - The company has not issued any future performance guidance or outlook for the upcoming quarters[13] Accounting and Reporting - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[21]